Clinical trial
Memantine for the Prevention of Cognitive Dysfunction and Negative Symptoms in…
NCT00148590 · M. Schaefer, MD, Other · Terminated
Key facts
| NCT number | NCT00148590 |
|---|---|
| Title | Memantine for the Prevention of Cognitive Dysfunction and Negative Symptoms in Patients With Acute Schizophrenia |
| Official title | Memantine add-on to Risperidon for Treatment of Negative Symptoms and Cognitive Dysfunction in Patients With Acute Schizophrenia: Results of a Proof of Concept Study |
| Lead sponsor | M. Schaefer, MD, Other |
| Collaborators | Stanley Medical Research Institute |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Schizophrenia |
| Intervention type | Drug |
| Interventions | Memantine, Placebo |
| Enrollment | 24 |
| Start date | Nov 1, 2005 |
| Primary completion | Jun 1, 2008 |
| Completion | Dec 1, 2008 |
| First posted | Sep 8, 2005 |
| Last update posted | Jun 27, 2019 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: